SLIM

Fund Description
The Obesity ETF seeks investment results that correspond generally to the performance, before fees and expenses, of an index which is designed to track the performance of companies globally that are positioned to profit from servicing the obese, including biotechnology, pharmaceutical, health care and medical device companies whose business is focused on obesity and obesity related disease including diabetes, high blood pressure, cholesterol, heart disease, stroke, and sleep apnea, and companies focused on weight loss programs, weight loss supplements, or plus sized apparel. The Fund pursues its investment objective by investing at least 80% of its net assets (plus any borrowings for investment purposes) in the stocks that comprise the Solactive Obesity Index ( Underlying Index ). The Underlying Index is designed to track the performance of companies globally that are positioned to profit from servicing the obese, including biotechnology, pharmaceutical, health care and medical device companies whose business is focused on obesity and obesity related disease including diabetes, high blood pressure, cholesterol, heart disease, stroke, and sleep apnea, and companies focused on weight loss programs, weight loss supplements, or plus sized apparel. Under normal circumstances, the Fund expects to invest substantially all of its assets in securities included in the Underlying Index, using a replication strategy as discussed below. The Fund may invest in companies of any capitalization, although at least 90% of the companies will have a capitalization of at least $100 million. The Fund may invest in foreign issuers, including emerging markets. Stocks included in the Underlying Index may include common shares traded on local exchanges, American Depositary Receipts ( ADRs ) and Global Depositary Receipts ( GDRs ). ADRs and GDRs represent ownership interests in shares of foreign companies that are held in financial institution custodial accounts, and are traded on exchanges in the United States and around the world. The Fund is classified as nondiversified, which allows it to hold larger positions in a smaller number of companies, compared to a fund that is classified as diversified.
Fund Profile
Fund Name The Obesity ETF
Fund Exchange Ticker SLIM
Fund Sponsor Janus
Fund ISIN US47103U5065
Net Expense Ratio 0.35 %
Fund Inception Date 8 June 2016
Fund Legal Structure ETF (Open end fund)
Exchange NASDAQ
Listing Country Code US
Fund Investment Objective
ETF Type Specific Global or ExUS Equities - Factor & Thematic
Asset Class Equities (Stocks)
Index Linked Passive
Index Name Solactive Obesity Index
Index Provider Solactive AG
Currency Hedged No
Inverse / Leveraged Not Applicable
Developed / Emerging Funds Combining Developed & Emerging Exposure
Market Capitalization Range Broad Market / Multi-Cap
Growth Value Core / Blend
Continent Not Applicable
Key Statistics
Return As of Date 22 March 2019
Asset Under Management 14.28 Million (USD)
1 Month Total Return 1.51 %
Year To Date Return 8.81 %
1 Year Total Return 9.06 %
3 Year Annualized Total Return
NAV 35.6971
Share Outstanding 400,001
Top 10 Holdings (22 March 2019)
Constituent Name Constituent Ticker Constituent Type Weighting
TAIWAN DOLLAR CASH
US DOLLAR CASH
ITAMAR MEDICAL LTD ITMR EQUI
DESTINATION XL GROUP INC DXLG EQUI
COHBAR INC CWBR EQUI
ZAFGEN INC ZFGN EQUI
APEX BIOTECHNOLOGY CORP 1733 EQUI
EKF DIAGNOSTICS HOLDINGS PLC EKF EQUI
POXEL SA POXEL EQUI
LEXICON PHARMACEUTICALS INC LXRX EQUI